Autologous Costal Cartilage Grafting for a Large Osteochondral Lesion of the Femoral Head
Changqing Zhang,Dexiao Du,Peichun Hsu,Yanyan Song,Youguang Gao,Zhenzhong Zhu,Weitao Jia,Youshui Gao,Minghao Zheng,Hongyi Zhu,Fu-Chou Hsiang,Shengbao Chen,Dongxu Jin,Jifang Sheng,Yigang Huang,Yong Feng,Junjie Gao,Guangyi Li,Jiewei Yin,Yao Chen,Chuanwen Jiang,Pengbo Luo,Shi‐Cong Tao,Chun Chen,Jinyu Zhu,Wei-Bin Yu
DOI: https://doi.org/10.2106/jbjs.22.00542
2022-01-01
Abstract:Background: There is currently no ideal treatment for osteochondral lesions of the femoral head (OLFH) in young patients. Methods: We performed a 1-year single-arm study and 2 additional years of follow-up of patients with a large (defined as >3 cm 2 ) OLFH treated with insertion of autologous costal cartilage graft (ACCG) to restore femoral head congruity after lesion debridement. Twenty patients ≤40 years old who had substantial hip pain and/or dysfunction after nonoperative treatment were enrolled at a single center. The primary outcome was the change in Harris hip score (HHS) from baseline to 12 months postoperatively. Secondary outcomes included the EuroQol visual analogue scale (EQ VAS), hip joint space width, subchondral integrity on computed tomography scanning, repair tissue status evaluated with the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score, and evaluation of cartilage biochemistry by delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC) and T2 mapping. Results: All 20 enrolled patients (31.02 ± 7.19 years old, 8 female and 12 male) completed the initial study and the 2 years of additional follow-up. The HHS improved from 61.89 ± 6.47 at baseline to 89.23 ± 2.62 at 12 months and 94.79 ± 2.72 at 36 months. The EQ VAS increased by 17.00 ± 8.77 at 12 months and by 21.70 ± 7.99 at 36 months (p < 0.001 for both). Complete integration of the ACCG with the bone was observed by 12 months in all 20 patients. The median MOCART score was 85 (interquartile range [IQR], 75 to 95) at 12 months and 75 (IQR, 65 to 85) at the last follow-up (range, 24 to 38 months). The ACCG demonstrated magnetic resonance properties very similar to hyaline cartilage; the median ratio between the relaxation times of the ACCG and recipient cartilage was 0.95 (IQR, 0.90 to 0.99) at 12 months and 0.97 (IQR, 0.92 to 1.00) at the last follow-up. Conclusions: ACCG is a feasible method for improving hip function and quality of life for at least 3 years in young patients who were unsatisfied with nonoperative treatment of an OLFH. Promising long-term outcomes may be possible because of the good integration between the recipient femoral head and the implanted ACCG. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.